Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $45 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan reiterates an Overweight rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintains a $45 price target.
June 22, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst reiterates Overweight rating on Crinetics Pharmaceuticals (CRNX) and maintains a $45 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald's analyst Charles Duncan indicates a positive outlook for Crinetics Pharmaceuticals. The maintained $45 price target suggests potential upside for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100